The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

por He, Yayi, Liu, Sangtian, Mattei, Jane, Bunn, Paul A, Zhou, Caicun, Chan, Daniel
Publicado 2018

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance

por Han, Ruoshuang, Jia, Yijun, Li, Xuefei, Zhao, Chao, Zhao, Sha, Liu, Sangtian, Liu, Yiwei, Chen, Donglai, Zhang, Qian, Liu, Xiaozhen, Shi, Jinpeng, Li, Jiayu, Zhou, Caicun
Publicado 2021

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

por Liu, Sangtian, Wu, Fengying, Li, Xuefei, Zhao, Chao, Jia, Yijun, Jia, Keyi, Han, Ruoshuang, Qiao, Meng, Li, Wei, Yu, Jia, Zhou, Fei, Xiong, Anwen, Chen, Bin, Fan, Jue, Ren, Shengxiang, Zhou, Caicun
Publicado 2021

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors

por Liu, Sangtian, Zhou, Fei, Liu, Zhiyu, Xiong, Anwen, Jia, Yijun, Zhao, Sha, Zhao, Chao, Li, Xuefei, Jiang, Tao, Han, Ruoshuang, Qiao, Meng, Liu, Yiwei, He, Yayi, Li, Jiayu, Li, Wei, Gao, Guanghui, Ren, Shengxiang, Su, Chunxia, Zhou, Caicun
Publicado 2020